Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
Metaboreflex activity in multiple sclerosis patients.
The Potential Roles of Aquaporin 4 in Alzheimer's Disease.
Autoimmune thyroiditis associated with neuromyelitis optica (NMO).
Patterns of Nonrandom Mating Within and Across 11 Major Psychiatric Disorders.
Test-retest reliability of four sensory measures in people with multiple sclerosis.
A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment.
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.
Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoactive intestinal peptide (VIP) concentrations in treatment-naïve humans with multiple sclerosis.
The Perspectives of Mesenchymal Stem Cell Therapy in the Treatment of Multiple Sclerosis.
Vision and vision-related outcome measures in multiple sclerosis.
Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.
Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.
Peroxisome proliferator activated receptor-γ agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: Effects on mitochondrial functions and differentiation.
The Increasing Prevalence of Multiple Sclerosis in New Zealand.
[Neurological complications during treatment of the tumor necrosis alpha inhibitors].
Systemic lupus erythematosus presented as extensive longitudinal myelitis.
Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus.
The Effect of Neural Lesion Type on Botulinum Toxin Dosage: A Retrospective Chart Review.
A Patient-defined "Best Case" of Multiple Sclerosis Related to the Use of Complementary and Alternative Medicine.
Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome.
Functional neuroimaging may quantify spinal cord demyelinating disease.
Tolerance of intravenous methylprednisolone for relapse treatment in demyelinating CNS disease.
TREM2 Function in Alzheimer's Disease and Neurodegeneration.
Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.
Pages
« first
‹ previous
…
584
585
586
587
588
589
590
591
592
…
next ›
last »